At Psych Congress 2018, 2 experts in the field of psychiatry squared off in a session called “The Great Debate in Contemporary Psychiatry: The Use of Antidepressants in Bipolar Disorder," about whether antidepressants should be used to treat patients with bipolar depression.
At Psych Congress 2018, 2 experts in the field of psychiatry squared off in a session called “The Great Debate in Contemporary Psychiatry: The Use of Antidepressants in Bipolar Disorder," about whether antidepressants should be used to treat patients with bipolar depression.
Nassir Ghaemi, MD, MPH, professor of psychiatry at Tufts University, presented the “con” side of the argument, while Joseph F. Goldberg, MD, clinical professor of psychiatry at the Icahn School of Medicine at Mount Sinai, presented the arguments “for” using antidepressants.
The Con Side
Ghaemi said he had 20 years of data to show that antidepressants don’t work, and that he wasn’t out to change anyone in the audience who had already made up their mind on the issue. But he said he hoped to influence a younger generation of clinicians.
He reviewed a meta-analysis of 6 studies looking at antidepressants in bipolar depression, which showed an overall effect size of 0.16, which he said was “very small.” He added that the effect size of antidepressants in major depressive disorder is 0.3.
The same analysis showed a lack of response rate as well as a lack of efficacy at 1 year, even when mood stabilizers were added.
“You might conclude then that these drugs are safe but useless,” he said. "There’s no point in using them.”
Citing 2 of his own studies, he also said antidepressants could worsen bipolar depression in people with rapid cycling and cause long-term manic episodes in people with bipolar depression.
The Pro Side
Goldberg said he didn’t think the issue about antidepressants and bipolar disorder was so black and white.
“Under what circumstances might antidepressants be more likely to be helpful or to be harmful, rather than to speak of the entirety of bipolar depression?” he asked, comparing the issue to discussions about the best way to treat cancer, hypertension, or infectious diseases.
For a subgroup of patients with bipolar depression, there may be value in antidepressant treatment. However, most antidepressants have not been studied in bipolar depression, and it is difficult to make generalizations with limited information, he said.
Goldberg said certain factors need to be considered when using antidepressants in patients with bipolar depression. These include:
However, there are many other factors that are linked with poor antidepressant response, he said, including severity, comorbidity, anxious features, psychosis, nonadherence, and more. These moderating factors have to be considered before deciding that antidepressants are the reason treatment is not working, he said.
“We really have to think about not just the diagnosis, but of the patient that has it,” he said.
In the end, the audience voted on their smartphones about who had the winning argument. Goldberg received 132 votes (50.6%), edging out Ghaemi by 3 votes (49.4%).
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More